NDAOPHTHALMICSUSPENSION/DROPS
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
5/8 — Partial
BYQLOVI (clobetasol propionate) by R-Pharm US is corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. First approved in 2024.
Drug data last refreshed 9h ago · AI intelligence enriched 12h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYQLOVI is a clobetasol propionate ophthalmic suspension approved in March 2024 for topical ocular use. It is a potent corticosteroid that reduces inflammation, itching, and vasodilation through inhibition of phospholipase A2 and downstream inflammatory mediators including prostaglandins and leukotrienes. The drug targets patients with inflammatory ocular conditions requiring topical corticosteroid therapy.
Growth9.6 years to LOE
Early-stage ophthalmic product in growth phase with limited current market penetration; expect focus on market development and team expansion over next 2-3 years.
Mechanism of Action
corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Started Dec 2022
60 enrolled
Cataracts Infantile
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Started Nov 2022
70 enrolled
Alopecia Areata
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Started Jun 2020
250 enrolled
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Started Jun 2020
215 enrolled
Cataract
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Started Jul 2013
28 enrolled
Plaque Psoriasis
Worked on BYQLOVI at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.